Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1

By  

International Archives of Allergy and Immunology, Vol. 138, Iss. 1, 2005-09 ,pp. : 59-66

Karger

Access to resources Recommend Favorite

Detection of Bet v1, Bet v2 and Bet v4 Specific IgE Antibodies in the Sera of Children and Adult Patients Allergic to Birch Pollen: Evaluation of Different IgE Reactivity Profiles Depending on Age and Local Sensitization

By  

International Archives of Allergy and Immunology, Vol. 154, Iss. 4, 2010-10 ,pp. : 278-285

Karger

Access to resources Recommend Favorite

Intranasal Treatment with a Recombinant Hypoallergenic Derivative of the Major Birch Pollen Allergen Bet v 1 Prevents Allergic Sensitization and Airway Inflammation in Mice

By  

International Archives of Allergy and Immunology, Vol. 126, Iss. 1, 2001-10 ,pp. : 68-77

Karger

Access to resources Recommend Favorite

Expression of a Human IgG4 Antibody, BAB2, with Specificity for the Major Birch Pollen Allergen, Bet v 1 in Escherichia coli: Recombinant BAB2 Fabs Enhance the Allergic Reaction

By  

International Archives of Allergy and Immunology, Vol. 118, Iss. 2-4, 1999-04 ,pp. : 190-192

Karger

Access to resources Recommend Favorite

Characterization of oral immune cells in birch pollen‐allergic patients: impact of the oral allergy syndrome and sublingual allergen immunotherapy on antigen‐presenting cells

By  

ALLERGY, Vol. 70, Iss. 4, 2015-04 ,pp. : 408-419

John Wiley & Sons Inc

Access to resources Recommend Favorite